Jefferies Financial Group Inc. Makes New Investment in Elanco Animal Health Incorporated (NYSE:ELAN)

Jefferies Financial Group Inc. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 80,899 shares of the company's stock, valued at approximately $980,000.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC boosted its position in Elanco Animal Health by 1,153.6% during the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after buying an additional 37,022,891 shares during the period. Norges Bank purchased a new stake in Elanco Animal Health during the 4th quarter valued at about $47,424,000. Brandes Investment Partners LP grew its position in Elanco Animal Health by 66.9% during the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock worth $69,405,000 after acquiring an additional 2,296,691 shares during the last quarter. Freestone Grove Partners LP purchased a new position in Elanco Animal Health in the 4th quarter worth approximately $20,396,000. Finally, Magnetar Financial LLC lifted its position in Elanco Animal Health by 13.7% in the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock valued at $145,711,000 after purchasing an additional 1,454,082 shares during the last quarter. Institutional investors own 97.48% of the company's stock.

Elanco Animal Health Trading Up 2.5%

NYSE:ELAN traded up $0.32 during midday trading on Monday, hitting $13.24. The stock had a trading volume of 7,555,799 shares, compared to its average volume of 5,052,520. The stock has a 50-day moving average of $10.11 and a 200 day moving average of $11.43. The company has a market capitalization of $6.58 billion, a price-to-earnings ratio of 33.10, a PEG ratio of 2.50 and a beta of 1.49. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.80. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.19 billion for the quarter, compared to the consensus estimate of $1.17 billion. During the same quarter in the prior year, the company earned $0.34 EPS. The business's revenue was down 1.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Elanco Animal Health Incorporated will post 0.91 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on ELAN shares. Barclays dropped their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the company a "buy" rating in a report on Monday. Morgan Stanley reduced their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, February 26th. Finally, UBS Group dropped their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $15.17.

Insider Activity

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the stock in a transaction on Friday, March 7th. The stock was bought at an average cost of $10.90 per share, for a total transaction of $109,000.00. Following the completion of the purchase, the director now directly owns 101,459 shares in the company, valued at approximately $1,105,903.10. The trade was a 10.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 0.89% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.